HSA approves the first JAK inhibitor for moderate-to-severe atopic dermatitis: baricitinib (Olumiant)

Share on email
Share on print
Share on whatsapp

Disease burden and current treatment landscape
Atopic dermatitis (AD) or atopic eczema is a common inflammatory skin condition that affects 20.8% of children aged 7 to 16 years in Singapore. While many children (about 70%) improve as . . .

Login or Sign Up as a healthcare professional to read the full article.

Share via

Share on email
Share on facebook
Share on whatsapp
Share on telegram
Share on twitter
Share on linkedin

Also worth reading